Drug Database
SC

Scherersol delivery systems (Polysol / Quadrisol / Cosol)

✓ Approved

Cardinal Health, Inc. · Small Molecule · Small Molecule

What is Scherersol delivery systems?

Scherersol delivery systems is a small molecule developed by Cardinal Health, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesPolysol, Quadrisol, Cosol
CompanyCardinal Health, Inc.
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved

Therapeutic Indications

Scherersol delivery systems is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedChemPlusChem2026-08-31

Synergistic Role of Co0 and Lewis Basic Sites for Transfer Hydrogenation of Substituted Nitroarenes by In Situ Hydrogen Generation.

Sharma Anitya A, Ramchiary Dhanmani D, Sharma Devendra D, Kumar Sahil S et al.

Designing green and efficient methods for synthesizing anilines remains a key challenge in synthetic organic chemistry. Hydrogenation of nitro compounds is one of the most significant and widely employed method for producing functionalized anilines. Consequently, designing catalytic systems capable of hydrogenating nitroarenes under environmentally benign and mild reaction conditions remains a challenge. In this regard, a highly efficient CoAl catalyst has been designed for the hydrogenation of nitroarenes to corresponding amines. Various structural, compositional, and morphological characterizations were done to understand the catalyst's structural and surface properties. The as-synthesized catalyst exhibits excellent activity for the transfer hydrogenation of 1-chloro-4-nitrobenzene to 4-chloroaniline, achieving 98% yield at 60 °C within 1.5 h in ethanol. The developed protocol demonstrated excellent activity for wide range of substituted nitroarenes. Structure-activity relationships of CoAl show that basic sites play a crucial role in the transfer hydrogenation. Furthermore, mechanistic investigations reveal that transfer hydrogenation occurs predominantly via a hydroxylamine-mediated pathway. Moreover, the catalyst maintains good catalytic activity up to four consecutive cycles. This method eliminates the need for high-pressure H2, offering a safe strategy for aromatic amine synthesis. The work demonstrates the potential of earth-abundant, non-noble-metal-based heterogeneous catalysts for hydrogenation reactions under environmentally benign conditions.

PubMedInternational journal of pharmaceutics: X2026-08-30

Optimizing nucleic acid delivery using PF14 peptide and lipid nanoparticle systems.

Daniele Delia D, Hein Zaw Myo ZM, Saher Osama O, El-Serafi Ibrahim I

Nucleic acid-based therapeutics are a rapidly expanding class of precision medicines capable of directly modulating gene expression. However, their clinical application is limited by challenges in cellular delivery, including large molecular size, hydrophilicity, and susceptibility to enzymatic degradation. To address these barriers, advanced delivery platforms such as cell-penetrating peptides and lipid nanoparticles (LNPs) have been developed. This study evaluates two delivery systems: the cell-penetrating peptide PepFect-14 (PF14) and LNP formulations, for enhancing nucleic acid delivery and cellular uptake. PF14 facilitates intracellular transport through peptide-nucleic acid complex formation, while LNPs protect cargo from degradation and can promote endosomal escape. Their performance was assessed under different conditions using luciferase-based reporter systems in HeLa cells. PF14-mediated delivery of the splice-switching oligonucleotide ON-705 in HeLa 705 cells showed efficient splice correction, with activity increasing in a dose- and molar ratio- dependent manner, reaching a plateau at a 1:10 ratio. Delivery efficiency was significantly influenced by formulation conditions, with Opti-MEM outperforming standard media and sugar-based buffers. Polymer excipients also affected activity as PVA18, PVA40, and PVP40 enhanced performance, while low molecular weight PVP reduced efficacy. In parallel, LNP-mediated delivery of luciferase mRNA in wild-type HeLa cells demonstrated robust, dose-dependent protein expression. Both systems maintained high cell viability (80-100%). Overall, these findings highlight the importance of formulation optimization in improving nucleic acid delivery and provide practical insights for enhancing peptide- and lipid-based therapeutic platforms.

PubMedZhonghua wai ke za zhi [Chinese journal of surgery]2026-08-30

[Advances and prospects of hemostatic strategies in hepatic surgery].

Xie T A TA, Peng S Y SY, Hou X T XT, Cai X J XJ

The liver is characterized by abundant blood supply and intricate anatomical architecture,rendering intraoperative and postoperative hemorrhage a primary clinical challenge. Conventional compression and suture ligation fail to enable precise perioperative hemorrhage prediction. Driven by the integration of precision medicine,artificial intelligence,and biomaterials,hemostatic strategies are undergoing a paradigm shift from passive compression to precise targeted intervention. This paper systematically reviews advances and future perspectives in hemostatic strategies for hepatic surgery. Preoperative individualized intervention is achieved via tranexamic acid prophylaxis,portal vein embolization,and radiological assessment; intraoperatively,Peng's curettage-suction technique enhances hemorrhage control; postoperatively,tiered "pharmacological-interventional-surgical" management allows proactive whole-course hemostatic regulation. Looking ahead,nano-drug delivery systems coupled with artificial intelligence closed-loop frameworks will facilitate the integrated development of hemostasis,liver regeneration promotion,and postoperative recurrence inhibition.

PubMedCommunications medicine2026-08-30

Progress and challenges in expanding access to clinical trials in pancreatic cancer.

Thang Sue S SS, Croagh Dan D, Ananda Sumitra S, Metz Andrew J AJ et al.

Clinical trials are essential for developing new cancer treatments and improving patient care. However, participation remains low across oncology and is particularly challenging for people with pancreatic cancer, who often experience rapid disease progression, limited treatment options, and short timeframes for trial enrolment. In this Review, we examine the factors that limit clinical trial participation in pancreatic cancer, including patient identification and referral, eligibility assessment, molecular testing, and trial delivery. We discuss how restrictive eligibility criteria, inconsistent integration of trial processes into routine care, variability in molecular testing, and logistical barriers reduce opportunities for participation. We also consider practical strategies to improve access, including earlier and more systematic trial identification, broader clinical eligibility criteria, timely molecular testing, more flexible trial designs, and decentralised models of care. Improving participation will require coordinated changes across clinical pathways, trial design, and healthcare systems to ensure that trial availability translates into equitable patient access.

PubMedJournal of the Royal Society of Medicine2026-08-30

Seven lessons for financial incentivisation schemes in healthcare: a qualitative study of NHS Resolution's Maternity Incentive Scheme.

Martin Graham Paul GP, Akdur Gizdem G, O'Hara Jane J, Dixon-Woods Mary M

Avoidable harm and variations in quality have remained persistent features of health systems, but the track record of financial incentives in driving improvement is mixed. Based on an evaluation of NHS Resolution's Maternity Incentive Scheme (MIS), which focuses on safety of maternity care in English NHS trusts, we identify generalisable principles to inform design of financial incentive schemes in healthcare. Qualitative process evaluation based on interviews with those involved in the design and delivery of MIS. Organisations involved in running MIS and organisations participating in the scheme. Thirty-five individuals were interviewed, including 17 involved in the national-level administration of MIS and 18 with experience of MIS at local level. Not applicable. We identified strengths, weaknesses and unintended consequences of the Scheme from the perspective of participants. MIS was seen by national-level stakeholders as having succeeded in elevating maternity safety in organisations' priorities and consolidating disparate safety requirements into a unified framework. They saw MIS as a clinically credible and system-owned mechanism for prioritisation. However, local-level participants reported significant administrative burdens, opportunity costs and challenges in interpreting and implementing its requirements. The Scheme's all-or-nothing reimbursement model, while reinforcing parity across the areas it covered, sometimes led to disproportionate focus on marginal issues and created perverse incentives when full compliance seemed unattainable. We identify seven key lessons for the design of incentive systems that might optimise their impact from the findings. Careful design of incentive schemes is vital to minimise unintended consequences. Lessons from MIS are relevant to broader healthcare system reform efforts and initiatives aiming to harness financial levers for quality improvement, such as those in the 10-Year Health Plan for England.

PubMedMaterials today. Bio2026-08-30

Targeted delivery of peptidoglycan hydrolases (PGH) via engineered extracellular vesicles (EVs) to clear intracellular bacterial infections.

Sabani Besmira B, Leone Martina M, Gasser Lynn L, Sumrall Eric E et al.

Bacterial infectious diseases remain a major global health threat due to increasing antibiotic resistance. Further complicating effective treatment, some pathogens such as Staphylococcus aureus persist within host cells. Peptidoglycan hydrolases (PGHs), including bacteriophage-derived endolysins, represent a promising class of novel antimicrobials due to their rapid bacteriolytic activity and low risk of resistance emergence. However, their clinical application is limited by an unfavourable PK profile and inefficient delivery into infected host cells. Here, we engineered extracellular vesicles (EVs) for the targeted, intracellular delivery of GH15, a novel endolysin against S. aureus. GH15-loaded EVs, functionalized with antibodies targeting αvβ3 integrin on bacterially infected cells, efficiently delivered GH15 into S. aureus-positive endothelial cells and macrophages in vitro and eliminated intracellular bacteria. In addition, GH15-loaded EVs promoted the clearance of intracellular bacteria in macrophages of infected zebrafish larvae in vivo. Our findings establish EVs as effective vehicles for intracellular delivery of antimicrobial enzymes and highlight their potential for the treatment of intracellular bacterial infections.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Scherersol delivery systems